Despite our increasing understanding of the molecular basis of cancer, many malignancies remain resistant to established forms of treatment. However, some cancers, such as melanoma, are relatively more responsive to modulation of immune function, possibly because the immune system can be induced to recognize mutant gene products that arise in these cells. Depending on treatment, 10% -20% of melanomas respond to some form of immunotherapy [42, 45, 54, 83, 84] . Conventional approaches to immunotherapy have utilized adjuvants, cytokines, or adoptive transfer of immune cells that have shown promise in animal models [13, 79, 92, 94, 106, 107] and in humans [44, 55, 80, 81] . More recently, molecular genetic interventions have been designed in an attempt to improve the efficacy of immunotherapy [63, 64, 78, 82] . The definition of tumor-associated genetic mutations has heightened interest in cancer as a target for gene therapy. Animal models have shown that genes encoding cell-surface antigens [72] , immunomodulatory cytokines [19, 98] or T-cell-costimulatory molecules [12, 100] can enhance the immune response to tumors. Based on these animal studies, several human gene transfer protocols have been designed to monitor safety, toxicity, gene expression, and the immune response to tumors [7, 10, 22, 28, 35, 51, 63, 70, 87, 89, 102] . Tumor cell growth can be directly related to their ability to evade the immune system. Tumors may actively inhibit the immune response by producing immunosuppressive factors [26, 69, 85] , or by inducing the development of regulatory cells with suppressive activity [3, 4, 11] . Since tumors arise from self tissue, they may be poorly immunogenic and therefore may be viewed as self by the immune system. Likewise, tumor cells may have a decreased capacity to present antigen because of deficiencies in β2-microglobulin, peptide transporter, or proteosome expression, all of which are requisite for effective class I antigen presentation [41, 76, 99] . Genetic modification of tumors shows promise as a therapeutic modality to increase the antigenicity of tumor cells as well as to enhance the production of immunopotentiating cytokines [7, 22, 27, 30, 53, 64, 89] . At the University of Michigan, Nabel and colleagues have developed a gene-transfer approach that utilizes the immunogenicity of a transplantation antigen to stimulate immune reactivity [63 -66] .
It has long been appreciated that the frequency of alloantigen-reactive T cells is quite high, even in naive animals that have not been previously immunized with alloantigens [52] . Since T cells with the potential to respond to foreign MHC molecules are dispersed throughout the immune system at frequencies 100 -1000 times greater than that of T cells responsive to nominal antigen, alloantigens are potent immunogens. Alloantigen-reactive T cells may directly recognize intact MHC proteins (direct recognition), or may respond to allogeneic MHC peptides that have been processed and presented in the context of self-MHC proteins by autologous antigen-presenting cells (indirect recognition) [91] . Direct recognition is likely the dominant pathway by which CD8 + CTL respond to allogeneic class I MHC, while the indirect pathway may play an important role in stimulating regulatory CD4 + helper T lymphocytes. Hence, gene transfer of a foreign MHC class I molecule has the potential of stimulating both effector and regulatory arms of the immune response (Fig. 1) . Thus, Nabel et al. proposed to deliver an allogeneic MHC class I gene into tumors to enhance the antitumor immune response [63 -66] .
In these studies, Nabel and collaborators utilized a novel approach for delivering genes into tumors [63 -66] . This approach relies on the direct transmission of recombinant genes into established tumors in vivo to modify them genetically as they grow in situ. In many gene-transfer models, tumor cells are cultured and transfected in vitro, then reintroduced into the host. Disadvantages of this approach include the need to establish an autologous tumor cell line for each patient, and the potential risk of altering the tumor by in vitro manipulation. In studies at the University of Michigan, the vector is transferred in vivo directly into tumor cells using intratumoral injection or, in some cases, catheter delivery [63 -66] . The direct in situ transfer of an immunostimulatory gene into the tumor provides an alternative therapeutic approach, which is not subject to these limitations. In addition, direct gene transfer may be performed immediately, thereby avoiding any delay in treatment posed by the need to establish and transfect tumor lines in vitro. Thus, in ongoing studies, tumor nodules are directly injected with a vector encoding an allogeneic MHC class I molecule.
E
x p e r i m e n t a l s y s t e m s
Direct gene transfer was initially tested in animal models using both retroviral vectors and DNA/liposome complexes [21, 59] . Utilizing a β-galactosidase reporter plasmid, recombinant gene expression could be readily detected after in vivo injection of DNA/liposome complexes or retroviral vectors in established murine CT26 tumors [72] . Further, gene expression was estimated to be 0.1% -1.0% at the sites of injection [29] . Thus, it was demonstrated that it was possible to transfer genes in situ directly into established tumors.
In an effort to show that a specific biological response could be induced at sites of recombinant gene transfer, an allogeneic class I gene was directly injected into BALB/ c(H-2K d )-tumor-bearing mice [72] . The foreign MHC I molecule is introduced  into tumors by direct gene transfer to enhance the antitumor immune response class I gene H-2K s was introduced into CT26 mouse colon adenocarcinoma (H-2K d ) tumors in vivo in an effort to stimulate tumor rejection. The H-2K class I antigen was chosen because it is strongly expressed on most tissues and can mediate an allogeneic rejection response. The H-2K s gene or the control (β-galactosidase reporter gene) was introduced directly into tumors using either a retroviral vector or DNA-liposome complexes. Mice receiving intratumor injections showed evidence of recombinant DNA by polymerase chain reaction (PCR) analysis and no evidence of inflammation or toxicity was detected.
Both the H-2K s retroviral vector and DNA/liposome complexes were found to signal the immune system to mount a response. Lymphocytes derived from mice bearing the H-2K s -, but not the β-galactosidase-transduced tumors, demonstrated a cytolytic response to H-2K s . Most significantly, lymphocytes derived from H-2K s -, but not β-galactosidase-transduced animals, recognized and lysed unmodified CT26 cells. Thus, transfer of the H-2K s gene induced immune reactivity against genetically unmodified tumor cells. Lysis was inhibited by an antibody against CD8, which blocks cytotoxic T lymphocytes (CTL) but not lymphokine-activated killer or antibody-dependent cellmediated cytotoxicity cell killing. Further, nude mice bearing CT26 showed no reduction in tumor growth after H-2K s injections, compared to controls. Thus, these data suggest that this immune response was T-cell-mediated, implying that immune stimulation by the alloantigen H-2K s induced specific T cell recognition of tumor-associated antigens not normally seen by the immune system. Specificity of tumor protection was evaluated in MCA-106(H-2K b )-tumor-bearing mice treated with intratumoral injections of H-2K s liposome complexes. Secondary inoculation at distant sites with parental MCA 106 tumor produced growth in only 20% of the mice whereas the unrelated syngeneic tumor B16BL/6 melanoma grew in 100% of the animals.
H-2K s -transduced tumors in unsensitized animals showed attenuation of growth, whereas, no antitumor effect was seen in unmodified or β-galactosidase-transduced tumor animals. In an attempt to optimize the antitumor response, mice were preimmunized with irradiated CT26 H-2K s tumor cells and given earlier and/or more frequent injections of vector. These strategies improved survival and attenuated tumor growth in contrast to β-galactosidasetransduced tumors where there was no difference compared with unmodified animals. Full tumor regression was achieved in some cases by increasing the number of injections and by delivery of H-2K s into tumors at an earlier stage. In addition, presensitization with CT26 H-2K s , followed by treatment with H-2K s DNA/liposome complex proved effective against MCA 106 H-2K b fibrosarcoma. Thus, presentation of H-2K s on a heterologous allogeneic cell line enhanced protection against a syngeneic tumor transduced in vivo with H-2K s .
The most important finding of these animal studies was that stimulation of the immune system by the foreign MHC class I antigen caused sensitization to otherwise unrecognized tumor antigens and provided a therapeutic effect for established malignancy in vivo. Since these studies demonstrated that direct gene transfer with an allogeneic class I molecule can provide a therapeutic effect against established malignancies, a human phase I clinical trial utilizing this approach was initiated at the University of Michigan to treat metastatic melanoma [63] .
The 
By utilizing DNA/liposome complexes, human melanoma nodules were genetically transduced in situ to express the foreign MHC class I molecule (HLA-B7) in an attempt to induce an antitumor immune response [64] . In the first of two phase I clinical trails, five HLA-B7-negative patients with stage IV melanoma refractory to conventional therapies were enrolled on the basis of the guidelines of the clinical protocol [63] . Each patient tolerated the treatment well with no acute complications. The eukaryotic expression vector plasmid utilized in this trial (pHLA-B7) was prepared by insertion of HLA-B7 cDNA into the Rous sarcoma virus β-globin plasmid [32, 61] . DNA/liposome complexes were prepared immediately prior to intratumor injection by adding lactated Ringer's solution to pHLA-B7, then combining it with the lipid dioleoyl phosphatidylethanolamine/3b-[N-(N9,N9-dimethylaminoethane)carbamoyl]-cholesterol liposome. Patients received a treatment schedule that consisted of either a single injection or a series of three injections of DNA/liposome complex (cumulative dose 0.29 -2.58 µg DNA) into a single melanoma nodule.
One of the primary goals of the first clinical trial was to determine whether there was any toxicity associated with DNA/liposome gene therapy [63, 64] . To monitor the potential toxicity of the DNA/liposome treatment, biochemical, hematological, and hemodynamic parameters were evaluated along with vital signs and cardiac rhythm. Analysis of serum biochemical parameters revealed no pattern of systemic abnormalities in these patients. Myocardial abnormalities were not detected by analysis of creatine kinase or its isoenzymes in the serum of treated patients, and no electrocardiographic changes or arrhythmias were noted. A major question regarding the future potential of this gene-delivery approach in humans was whether an immune response would be generated to DNA. Such a response or the formation of antibodies to DNA could induce resistance to treatment or signal the development of autoimmunity. In these studies, there were no detectable increases in anti-DNA antibodies and no clinical evidence of autoimmunity. Thus, it appears that foreign DNA is not highly immunogenic in vivo and that the immune response is unlikely to limit in vivo gene transfer by DNA/liposome complexes.
Injected tumor nodules were biopsied 3 -7 days after gene transfer and tissue was analyzed for the presence of plasmid DNA, mRNA coding for HLA-B7, and expression of HLA-B7 protein [64] . RNA encoding HLA-B7 was detected by PCR after incubation with reverse transcriptase but not in its absence. Further, HLA-B7 protein expression was confirmed in biopsy samples by immunohistochemistry. The recombinant protein was detected at frequencies ranging from 1% to 10% of tumor cells near the site of injection. Also, it is important to note that plasmid was not detected at any time in the blood following gene transfer, suggesting that the DNA remained localized to the site of injection.
Cytolytic T cell responses were evaluated to determine whether gene transfer resulted in altered antitumor immunity [64] . Tumor-specific CTL were detected in both the peripheral blood and from tumor-infiltrating lymphocytes (TIL) in patients evaluated after gene transfer. These CTL lysed autologous melanoma specifically and in a dosedependent fashion. Although there were no pretreatment samples available for a comparison, the ability to detect T cells specific for melanoma in the peripheral blood is unusual and thus likely to be treatment-related. Further, in 1 patient where a pretreatment sample was available, a fivefold increase in the frequency of HLA-B7-reactive CTL precursors was detected after treatment. These findings suggest that expression of the foreign MHC gene after gene transfer altered the reactivity of the immune system in these patients.
In regard to tumor growth, 1 patient showed complete regression of a HLA-B7-treated cutaneous nodule [64] . In addition, over the same period, metastatic lesions at distant sites also displayed complete regression, including lesions on the upper and lower back, upper arm, abdomen, and a pulmonary nodule. It is interesting to note that the patient whose tumors regressed after treatment received injections in cutaneous nodules, whereas, in the other patients, metastatic lymph nodes were treated. Thus, lymph node replacement by tumor may be associated with a greater degree of immunosuppression, or dermal dendritic cells may provide more efficient antigen presentation and immune stimulation. Therefore, on the basis of these findings, a second phase I clinical trial was initiated in which pHLA-B7 was delivered by direct injection into cutaneous tumor nodules.
The first clinical trial determined the feasibility and safety of directly transferring genes into humans. In addition, it provided important information regarding the dosage of DNA and lipid required for expression and biological effect. Thus, on the basis of findings of the first study, modifications of plasmid and lipid were subsequently designed to improve clinical efficacy. The improved plasmid vector included the gene encoding β2-microglobulin, with which class I MHC genes normally associate. Ordinarily, these two gene products are co-transported to the cell surface with both molecules being required in order to express a stable class I protein on the cell [43, 77] . Loss of β2-microglobulin is one mechanism by which tumor cells lose stable class I expression, thus becoming less immunogenic, and are able to evade the immune system [17, 25, 36, 38, 77, 104] . Several tumor cell lines that exhibit low levels of class I MHC proteins have been shown to be less oncogenic when expression vectors encoding the relevant class I MHC antigen are introduced into them [34, 37, 48, 97, 103] . Further, Nabel et al. have found that the inclusion of the β2-microglobulin gene on the same plasmid as HLA-B7 allows for the expression of class I in otherwise resistant cells and improves expression in other cells, thus, overcoming a potential mechanism of resistance [65] .
In addition to an improved expression vector, a new cationic lipid formulation was developed (1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl-ammonium bromide utilized with dioleoyl phosphatidylethanolamine [20, 86] . This new formulation improved expression up to tenfold compared to the previous formulation in in vitro transfection studies. What is more important, this formulation does not aggregate at high concentrations, and this characteristic allows higher absolute concentrations of DNA and liposomes to be introduced into experimental animals without toxicity. Thus, in the second phase I clinical trial, much higher doses (more than 100-fold) were able to be administered without toxicity [65, 66] .
Utilizing the improved vector and lipid, the second study enrolled 10 HLA-B7-negative patients with stage IV melanoma, who were all unresponsive to standard treatments [65, 66] . Patients were divided into four groups, each of which received a different dose of DNA/liposome complex (3, 30, 100, or 300 µg DNA) three times biweekly for a total of three treatments. To monitor the potential toxicity of the DNA/liposome treatment, biochemical, hematological and hemodynamic parameters were again evaluated. No abnormalities were found in the acute period (3 -7 days) or up to 2 months after the initial gene transfer. As in the first study, no increases in anti-DNA antibodies were detected in patients and there was no clinical evidence of autoimmune phenomena. Thus, these data support the previous observations that DNA is not highly immunogenic in vivo in humans and an immune response to DNA/liposome complexes is unlikely to limit direct gene transfer with this vector or other forms of DNA.
Patient tumor samples were obtained by core needle biopsies before and at 1 -3 days after intratumoral injection of HLA-B7 DNA/liposome complexes [65, 66] . Reverse transcriptase (RT)/PCR was performed on biopsy samples of injected tumor to confirm recombinant HLA-B7 gene expression within treated tumors, and blood samples obtained immediately before and at multiple times after injection were analyzed for the presence of plasmid DNA by PCR. In these patients, plasmid DNA was not detected at any time in the blood following gene transfer, indicating that the DNA remained localized to the site of injection. In addition, RNA coding for HLA-B7 was detected by PCR after incubation with reverse transcriptase but not in its absence, and HLA-B7 protein expression was verified in biopsy tissue by immunohistochemical staining. Similar to the first study, recombinant protein was detected at frequencies ranging from 1% to 10% of tumor cells near the site of injection [64, 66] . Thus, it was demonstrated that gene expression can be consistently achieved without toxicity by this method of gene transfer.
To determine whether the introduction of a foreign MHC gene could alter the T cell response to tumors, tumor biopsy samples were analyzed for the presence of infiltrating T cells before and after gene transfer [66] . Immunostaining with αCD3 in tumor nodules revealed CD3 + cells at the margins of tumors with relatively few cells within the parenchyma before treatment. After gene transfer, an increase in tumor-infiltrating lymphocytes was detected. In cases where tumor growth was not affected, this pattern of infiltration was not maintained. Biopsy samples from a patient who responded to treatment were further investigated by immunostaining for markers of lymphocyte activation. Prior to gene transfer, there were numerous HLA-DR-positive dendritic cells in and around melanoma cells, with fewer than 10% expressing the costimulatory molecules CD80 or CD86. After gene therapy, the injected melanoma sites contained dendritic cells in and around the tumor that were HLA-DR-positive, and numerous peritumoral dendritic cells were seen that were CD80-and CD86-positive. CD80 (B7.1) and CD86 (B7.2) are important costimulatory molecules necessary for T cell activation [1, 40, 101] . Thus, the finding of increased CD80 and CD86 expression, along with increased infiltration of CD3 + cells in treated tumors, suggested that expression of a foreign MHC gene by direct gene transfer may have enhanced the immune response to tumors in some patients.
In an effort to evaluate altered T cell tumor immunity, limiting-dilution analysis was utilized to quantify autologous tumor-specific CTL in the blood of patients, as well as in TIL populations derived from tumor before and after HLA-B7 gene transfer [66] . The frequency of autologous tumor-specific CTL was quantified in the peripheral blood of 5 evaluable patients. Of the 5 patients, 4 had rare to undetectable frequencies before treatment, and 4 remained unchanged following gene transfer. However, it should be noted that 1 individual did show an increase after treatment, but the cytolytic activity of these cells was weak. Hence, in most patients, HLA-B7 gene transfer did not markedly alter the frequency of autologous tumor-specific CTL in the peripheral blood, as might be expected from other model systems [8] .
Cytolysis assays revealed that TIL populations generally showed a high degree of specific lysis of autologous but not heterologous melanoma or natural killer target cells in vitro [66] . TIL obtained prior to treatment possessed weak to negative cytolytic activity for autologous tumor; however, the lytic activity of post-treatment-derived TIL was increased in the patients evaluated. In addition, the frequencies of CTL precursors within these TIL populations were determined by limiting-dilution analysis. In the few patients evaluated, gene transfer increased the CTL precursor frequency of autologous tumor-reactive TIL. Hence, the frequency of CTL precursor cells paralleled the direct lytic activity of TIL in these patients. These findings suggest that HLA-B7 gene transfer may result in an adjuvant effect where an immune response is generated to parental tumor antigens.
In regard to tumor growth, 1 patient showed partial regression (50%) of a treated nodule [66] . In this patient, at least one metastatic lesion at a distant site (inguinal lymph node mass) displayed a similar partial regression over the same period. However, three other distant sites in this same patient showed no regression. When one of these latter tumor nodules was subsequently treated by HLA-B7 gene transfer, reduction in tumor size was observed, although to a lesser degree than for the first lesion (10% -20%). Together, these data suggest that introduction of the HLA-B7 gene may lead in some cases to antitumor effects at the treatment site and at some distant site of disease.
Since this 1 patient showed evidence of local and systemic responses to HLA-B7 gene transfer, and TIL cultures showed specific cytolytic activity against autologous tumors, gene transfer was combined with immunotherapy in this patient. TIL obtained from tumor nodules that had received injections with HLA-B7 DNA/liposome complexes were expanded and characterized. These TIL cultures mediated tumor-specific lysis of autologous tumor in standard cytotoxic assays. In addition, these TIL demonstrated significantly enhanced release of granulocytemacrophage-colony-stimulating factor (GM-CSF), interferon γ (IFNγ) and tumor necrosis factor α (TNFα) in response to autologous tumor relative to TIL obtained prior to HLA-B7 gene transfer [66] . Several studies have reported that tumor-specific release of cytokines by immune lymphoid cells correlates with therapeutic efficacy in adoptive-transfer systems [2, 5, 31, 88] . Thus, approximately 10 11 cells were adoptively transferred back to the patient and this was followed by interleukin-2 (IL-2) infusion. Following two TIL treatments, this patient manifested a complete regression of residual disease and this remission has persisted now for more than 1 year after the initial treatment.
Considering that HLA-B7 gene transfer resulted in enhanced CTL and cytokine production in response to autologous, nontransduced tumor, it was important to address whether the enhanced antitumor response was due to the expansion or differentiation of cells that existed before treatment, or if it reflected recruitment of additional T cell populations. Since distinct T cells express different T cell receptors which impart distinct antigen specificities, these cells may be identified by virtue of Vβ expression. Thus, to address whether the enhanced antitumor response was due to preexisting cells or newly recruited cells, TIL Vβ expression was evaluated [15] . TIL generated from melanoma lesions are primarily CD3 + T cells that express an α/β T cell receptor [73] . Antigen specificity is imparted by rearrangement of the variable (V), diversity (D), and joining (J) segments for the β locus and of V and J segments of the α locus [56] . In our studies, TIL were isolated from cutaneous melanoma biopsies before and after HLA-B7 gene transfer, expanded in IL-2 by standard techniques for approximately 4 weeks, and then analyzed for T cell receptor Vβ usage by quantitative RT-PCR [16] . Prior to gene transfer, TIL Vβ usage was found to be highly restricted with only one to four Vβ families being expressed, and one or two of these families representing more than 90% of the repertoire. As anticipated, TIL Vβ usage varied among patients expressing different HLA types. However, Vβ13 was over represented in that 6 of 8 patients utilized Vβ13 as a dominant family, regardless of HLA type. Following HLA-B7 gene transfer, TIL Vβ usage was markedly altered: (1) Vβ families that dominated following gene transfer differed from the Vβ families utilized by TIL prior to treatment, and (2) introduction of the HLA-B7 gene resulted in a more diverse repertoire with an increase in the number of Vβ families represented. In 2 patients, TIL were evaluated before treatment and from multiple, distinct melanoma nodules following gene transfer. In these 2 patients, a comparison was made between TIL Vβ profiles obtained after treatment from nodules that had been injected with the HLA-B7 gene and those that had been left untreated. Interestingly, the Vβ repertoires of TIL from uninjected nodules following HLA-B7 treatment were similar to those of TIL from injected nodules, rather than to those of pretreatment TIL. These data demonstrate a direct immunological effect of foreign MHC gene transfer into human melanoma, and suggest that local expression of an allogeneic MHC molecule generates systemic alterations in the antitumor immune response.
Restricted Vβ usage has been reported for TIL derived from a variety of tumor types [6, 24, 33, 71, 75, 90, 96] , though the degree of Vβ restriction may vary. The highly restricted Vβ usage by pretreatment TIL in our studies suggests that a limited number of immunodominant tumor antigens were recognized by pretreatment TIL. A major point to emphasize is that HLA-B7 gene transfer altered the repertoire of T cells that surfaced in TIL cultures, indicating that distinct T cell populations, probably with distinct antigen specificities, were activated in vivo. In most cases, the T cells that dominated pretreatment TIL cultures were replaced following gene transfer, giving rise to a more diverse population. This effect was systemic, in that TIL derived from distant, uninjected nodules from HLA-B7-treated patients exhibited similar altered Vβ profiles. Hence, T cells induced by HLA-B7 gene transfer have a selective advantage over cells that were initially recovered from pretreatment tumor nodules. The mechanisms responsible for this altered dominance are currently not known, but may include in situ expansion or an enhanced state of activation of these T cells.
The biological consequence of altered Vβ expression by TIL after HLA-B7 gene transfer is not fully understood. Following gene transfer, both the pHLA-B7-injected and uninjected nodules of one patient underwent partial regression [66] . This patient subsequently received TIL therapy utilizing post-treatment TIL that expressed a heterogeneous Vβ repertoire. This TIL therapy resulted in complete regression of all melanoma nodules, suggesting potent in vivo antitumor activity of the TIL induced by HLA-B7 gene transfer. It should be noted that this patient's posttreatment TIL expressed the greatest degree of Vβ heterogeneity of all those assessed in this study [15] .
Since TIL obtained from distinct, untreated nodules expressed the same altered Vβ profile as those obtained from nodules that were injected with the HLA-B7 gene, it is unlikely that all cells in these TIL populations are reactive with HLA-B7. Further, HLA-B7 gene transfer increased the ability of TIL to lyse autologous, nontransduced (HLA-B7-negative) tumor cells in some patients [66] . It is possible that HLA-B7 gene therapy produces an adjuvant effect, thus stimulating the development of additional tumor-reactive T cells expressing distinct TCR. One hypothesis is that HLA-B7-reactive T cells respond to the locally expressed alloantigen, which may be presented directly to CD8 + cells, as well as indirectly by infiltrating macrophages to CD4 + cells (Fig. 1) . Cytokines produced by these HLA-B7-reactive cells could potentiate and expand the antitumor immune response at several levels: (1) providing help for the development of additional tumor-reactive T cell clones, (2) up-regulating MHC and therefore antigen expression by tumor cells [18, 93] , and (3) increasing antigen-presenting cell recruitment and function within the tumor [16] . Cytokines can participate in the antitumor response whether by a direct action on cell growth or by activating cellular immunity. For example, the cytostatic effects of TNFα [67, 68] and lymphotoxin [74] can result in neoplastic cell death. In addition, IFNγ markedly increases class I MHC cell-surface expression [46, 47] and synergizes with TNFα in producing this effect [67, 68] . Further, colonystimulating factors such as G-CSF and GM-CSF activate neutrophils and macrophages to lyse tumor cells directly [14] and IL-2 activates leu19 + NK cells to generate lymphokine-activated killer cells (LAK) capable of lysing autologous, syngeneic or allogeneic tumor cells but not normal cells [39, 49] . Finally, IL-4 also generates LAK cells and acts synergistically with IL-2 in the generation of tumor-specific killer cells [57] . In contrast to most therapies, stimulation of the immune system by a foreign MHC antigen may cause sensitization of otherwise unrecognized tumor antigens and provide a therapeutic effect for established tumors in vivo. Studies utilizing such an allogeneic molecule have demonstrated that a recombinant gene can be directly introduced in vivo and that the gene product is expressed by host cells. The treatment is safe and there is no observed toxicity [63 -66] .
In addition, these studies have provided insight into mechanisms of generating tumor immunity. The next steps will be to analyze further the mechanisms of the antitumor immune response and to improve its efficacy. Efficacy may be improved by combining gene therapy with other forms of treatment. Gene-transfer approaches could be used in combination with existing treatments such as cytokines or adoptive T cell therapy. In addition, it would be possible to include other genes along with HLA-B7 in future studies.
For example, such genes might encode for anti-proliferative agents, cytokines, growth-factor antagonists, or inhibitors of angiogenesis. Another potential improvement would be to deliver recombinant genes to specific sites by catheter in vivo, in an effort to introduce gene products into metastatic lesions and into the tumor microcirculation. This intervention provides the ability to transduce a larger percentage of cells within the tumor in order to achieve greater efficacy of gene expression while, at the same time, minimizing the potential for inadvertent seeding of tumor cells to distant sites. Particularly for the in vivo catheter delivery, it may be appropriate to utilize this approach on malignancies other than melanoma, such as colon carcinoma, renal cell carcinoma, or breast cancer. Early studies using this approach demonstrated that specific reporter genes could be expressed in vivo [58, 59] and subsequent studies have shown that specific biological responses can be induced at sites of recombinant gene transfer via this delivery route [61, 62, 72] . Although additional patients will be required to confirm the consistency of the antitumor immune response, it is encouraging that patients in separate clinical studies have shown a response to treatment. In addition to the patients described here [63 -66] , 7 of 14 patients treated at an independent site have shown local regression in response to this gene-transfer procedure [66] . Clearly, further clinical studies are warranted to establish the efficacy of this genedelivery approach for the treatment of melanoma and other cancers. The ability to alter local or regional immune responses by gene transfer may provide an alternative method to eliminate residual disease and complement current immunological treatments for malignancies.
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